grants from Bayer, AbbVie, and Boehringer Ingelheim, and consultation fee from Reata, outside the submitted work. T. I. Chang reports receiving consulting fees from Fresenius Medical Care Renal Therapies Group, LLC; Janssen Research and Development, LLC; Novo Nordisk; and Tricida Inc. and grant support from Satellite Health Care for work unrelated to this manuscript. R. Boucher, G. M. Chertow, A. K. Cheung, T. Greene, H. Kramer, G. Wei, and P. K. Whelton have nothing to disclose. Funding Statistical analyses and preparation of this manuscript were supported by NIDDK grants R21HL145494, R01DK115814, and R21DK106574, and the University of Utah Study Design and Biostatistics Center funded in part from National Center for Research Resources Public Health Services research grants UL1-RR025764 and C06-RR11234. The Systolic Blood Pressure Intervention Trial was funded with federal funds from the National Institutes of Health, including NHLBI; NIDDK; National Institute on Aging; and National Institute of Neurological Disorders and Stroke contracts George Washington University: UL1TR000075; University of California, Davis: UL1TR000002; University of Florida: UL1TR000064; University of Michigan: UL1TR000433; and Tulane University: P30GM103337 Center of Biomedical Research Excellence Award National Institute of General Medical Sciences. 374 KIDNEY360 Supplemental Material This article contains supplemental material online at http://kidney360.asnjournals.org/lookup/suppl/doi:10.34067/ KID.0000982019/-/DCSupplemental. Supplemental Figure 1. Cubic spline regression models showing hazard ratios with pointwise 95% confidence intervals for the association of baseline diastolic BP as a continuous variable with the primary composite end point and all-cause death and for the effect of the randomized systolic BP intervention across a range of baseline diastolic BPs on the primary composite end point and allcause death in the Systolic Blood Pressure Intervention Trial participants with baseline CKD. Supplemental Figure 2. Forest plots showing hazard ratios and 95% confidence intervals for the effect of the randomized systolic BP intervention on the primary composite end point and all-cause death for the entire CKD cohort and by baseline diastolic BP tertile. References 1. Vidal-Petiot E, Ford I, Greenlaw N, Ferrari R, Fox KM, Tardif JC, Tendera M, Tavazzi L, Bhatt DL, Steg PG; CLARIFY Investigators: Cardiovascular event rates and mortality according to achieved systolic and diastolic blood pressure in patients with stable coronary artery disease: An international cohort study. Lancet 388: 2142–2152, 2016 2. Bangalore S, Messerli FH, Wun CC, Zuckerman AL, DeMicco D, Kostis JB, LaRosa JC; Treating to New Targets Steering Committee and Investigators: J-curve revisited: An analysis of blood pressure and cardiovascular events in the Treating to New Targets (TNT) Trial. Eur Heart J 31: 2897–2908, 2010 3. Protogerou AD, Safar ME, Iaria P, Safar H, Le Dudal K, Filipovsky J, Henry O, Ducimetie`re P, Blacher J: Diastolic blood pressure and mortality in the elderly with cardiovascular disease. Hypertension 50: 172–180, 2007 4. Itoga NK, Tawfik DS, Lee CK, Maruyama S, Leeper NJ, Chang TI: Association of blood pressure measurements with peripheral artery disease events. Circulation 138: 1805–1814, 2018 5. Sedaghat S, Mattace-Raso FUS, Hoorn EJ, Uitterlinden AG, Hofman A, Ikram MA, Franco OH, Dehghan A: Arterial stiffness and decline in kidney function. Clin J Am Soc Nephrol 10: 2190–2197, 2015 6. Covic A, Kanbay M, Voroneanu L, Turgut F, Serban DN, Serban IL, Goldsmith DJ: Vascular calcification in chronic kidney disease. Clin Sci (Lond) 119: 111–121, 2010 7. Beddhu S, Chertow GM, Cheung AK, Cushman WC, Rahman M, Greene T, Wei G, Campbell RC, Conroy M, Freedman BI, Haley W, Horwitz E, Kitzman D, Lash J, Papademetriou V, Pisoni R, Riessen E, Rosendorff C, Watnick SG, Whittle J, Whelton PK; SPRINT Research Group: Influence of baseline diastolic blood pressure on effects of intensive compared with standard blood pressure control. Circulation 137: 134–143, 2018 8. Ambrosius WT, Sink KM, Foy CG, Berlowitz DR, Cheung AK, Cushman WC, Fine LJ, Goff DC Jr., Johnson KC, Killeen AA, Lewis CE, Oparil S, Reboussin DM, Rocco MV, Snyder JK, Williamson JD, Wright JT Jr., Whelton PK; SPRINT Study Research Group: The design and rationale of a multicenter clinical trial comparing two strategies for control of systolic blood pressure: The systolic blood pressure intervention trial (SPRINT). Clin Trials 11: 532–546, 2014 9. Wright JT Jr, Williamson JD, Whelton PK, Snyder JK, Sink KM, Rocco MV, Reboussin DM, Rahman M, Oparil S, Lewis CE, Kimmel PL, Johnson KC, Goff DC Jr, Fine LJ, Cutler JA, Cushman WC, Cheung AK, Ambrosius WT; SPRINT Research Group: A randomized trial of intensive versus standard blood-pressure control [ published correction appears in N Engl J Med 377: 2506, 2017]. N Engl J Med 373: 2103–2116, 2015 10. Williamson JD, Pajewski NM, Auchus AP, Bryan RN, Chelune G, Cheung AK, Cleveland ML, Coker LH, Crowe MG, Cushman WC, Cutler JA, Davatzikos C, Desiderio L, Erus G, Fine LJ, Gaussoin SA, Harris D, Hsieh MK, Johnson KC, Kimmel PL, Tamura MK, Launer LJ, Lerner AJ, Lewis CE, Martindale-Adams J, Moy CS, Nasrallah IM, Nichols LO, Oparil S, Ogrocki PK, Rahman M, Rapp SR, Reboussin DM, Rocco MV, Sachs BC, Sink